Skip to main content
Premium Trial:

Request an Annual Quote

Scott Kahn, Robert Tien, Rebecca Caffrey, Michael Kallelis


Scott Kahn has been appointed as vice president and chief information officer of Illumina, the company said last week. He joins Illumina from Accelrys, where he was chief scientific officer. Kahn holds a PhD in theoretical organic chemistry from the University of California, Irvine. An Accelrys spokesman told BioInform, Pharmacogenomics Reporter's sister publication, that Kahn left the company a month ago, and that Accelrys is currently seeking a replacement.

Robert Tien, a director of Orchid BioSciences, will not stand for re-election at the company's next annual meeting of stockholders, Orchid said in an SEC filing earlier this month.

Rebecca Caffrey has become business development manager of tissue provider Asterand, the Detroit, Mich.-based company said this week. She joins the company from Ciphergen Biosystems, where she was a business development and product manager.

Michael Kallelis has become vice president of manufacturing of Archemix, the Cambridge, Mass.-based aptamer company said on Tuesday. He comes to Archemix from Avecia Biotechnology, where he was executive vice president and general manager and managed an oligonucleotide synthesis plant. In the past, he also held positions at Boston BioSystems, BioSepra, and Millipore.


Filed under

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.